99Tc-MDP Versus Celecoxib Treatment in Patients With Knee Osteoarthritis

What this Trial Is About

Osteoarthritis OA of the knee is a common and increasing form of arthritis worldwide, particularly affecting older adults. This research aims to compare the effects of 99Tc-MDP, a drug previously used for rheumatoid arthritis and other bone diseases, with celecoxib, a commonly prescribed oral anti-inflammatory medication, in patients with knee OA. The study is designed to better understand how these treatments may help control symptoms and potentially slow disease progression in this population. Participants will receive either 99Tc-MDP or celecoxib. The 99Tc-MDP group will be given 15 mg of the drug intravenously in 100 ml of normal saline twice weekly for 5 weeks, then weekly for 10 weeks, every 2 weeks for another 10 weeks, and finally once a month for 6 months. The celecoxib group will take a 200 mg capsule orally once daily. The study is non-randomized and open-label, meaning both participants and researchers know which treatment is given. Throughout the study, participants will be assessed at baseline and at 6 and 12 months after treatment starts. Evaluations will include pain, stiffness, and knee joint function, as well as quality of life, disease staging, and imaging measurements using bone scans. Safety will be monitored by tracking any adverse events at 3, 6, and 12 months. The total participation time covers these follow-up periods to understand the treatments effects over time.

99Tc-MDP Treatment for Knee Osteoarthritis